| Literature DB >> 35183435 |
Tamta Tkhilaishvili1, Evgenij Potapov2, Christoph Starck2, Johanna Mulzer3, Volkmar Falk4, Andrej Trampuz5, Felix Schoenrath2.
Abstract
Conventional antimicrobials have low or no activity against multidrug-resistant or chronic implant-associated infections. Lytic bacteriophages can rapidly and selectively kill bacteria, and can be combined with antibiotics. However, clinical experience of bacteriophage therapy in patients with cardiovascular infections is limited. We documented the outcome and safety of intravenous and local adjunctive bacteriophage therapy, to treat chronic relapsing cardiovascular implant infections at our institution.Entities:
Keywords: alternative therapy; bacteriophage therapy; biofilm infections; cardiovascular implant infections; multidrug resistant infections
Mesh:
Substances:
Year: 2022 PMID: 35183435 DOI: 10.1016/j.healun.2022.01.018
Source DB: PubMed Journal: J Heart Lung Transplant ISSN: 1053-2498 Impact factor: 10.247